However, the precise role of FGF/FGFR signaling pathway in CLL B-cell survival and apoptotic resistance remains undefined.
To explore whether bFGF has a role in CLL B-cell survival, we first examined the expression profile of FGFR1/R2/R3/R4 in CLL B cells by western blot analysis using specific antibodies. We find that CLL B cells overexpress FGFR3 significantly (Figure 1a ). Although a low-level expression of FGFR1/R2/R4 was noted in CLL B cells, these levels were no significantly different than those detected in normal B cells (Supplementary Figure 1A) . It appears that CLL B cells predominantly express two splice variants of FGFR3 with molecular weights of~100/125 kDa in western blots. Thus, the banding pattern of FGFR3 as shown in Figure 1a was further confirmed using a different antibody to FGFR3 (Supplementary Figure 1B) . Although several splice variants are known to exist for each member of the FGFR family, 3 the mechanism of their regulation(s) is largely undefined.
To validate our findings that CLL B cells primarily express FGFR3, individual FGFRs were immunoprecipitated from equal amount of lysates from CLL B cells or normal B cells followed by western blot analyses to detect FGFR1/R2/R3/R4. As expected, we detected significantly elevated levels of Figure 2) using specific primers (see Supplementary Methods) and confirmed by sequencing the PCR products. Of interest, we also found that exons-8 and -9 of FGFR3 are largely absent in CLL B cells as reverse primers designed for exon-8 or -9 could not amplify the transcript using the forward primer from exon-6, whereas the reverse primer for exon-11 and forward primer at exon-6 amplified FGFR3 transcript (Supplementary Figure 2) . Deletions of FGFR3 exons-8-10 have been reported in multiple human malignancies including breast, squamous and osteosarcoma. 4 However, an in-depth study is needed to define more clearly the nature of FGFR3 regulation in CLL B cells. In total, our results suggest that CLL B cells overexpress primarily FGFR3.
Phosphorylation at tyrosine residues 653 and 654 (Y653/654) in the kinase domain is important for catalytic activity of the activated FGFRs and its downstream signaling. 5 To that end we detected that FGFRs in CLL B cells remain constitutively phosphorylated at Y653/654 tyrosine residues ( Figure 1h) ; indicating that the FGFR signaling pathway is catalytically active. Of interest, we have also detected that CLL B cells co-express both P-FGFR and P-Axl (Figure 1i ), suggesting that there may exist a possible functional link between these two RTKs. However, as CLL B cells overexpress FGFR3, we hypothesized that FGFR3 remains as the constitutively active FGFR. Indeed FGFR3 displays elevated levels of phosphorylation at Y653/654 residues (Figure 1j ). Further analysis demonstrates that FGFR3 in CLL B cells remains as a highly phosphorylated RTK (Figure 1k ). Together, these findings suggest that (i) FGFR signaling is a constitutively active pathway in CLL B cells and that (ii), the heavily phosphorylated FGFR3 likely drives the FGFR signal in CLL B cells.
To define the mechanism of constitutive phosphorylation on FGFRs, CLL B cells were treated with recombinant-bFGF or a bFGF-neutralizing antibody and analyzed the cells for alteration of P-FGFR levels. We found that neutralizing antibody treatment or recombinant-bFGF addition to CLL B-cell culture could not alter the phosphorylation levels on FGFRs from the basal level (Supplementary Figure 3) ; suggesting that FGFR phosphorylation in CLL B cells is likely independent of any autocrine/paracrine loop. Of interest, a recent report suggests that Axl, which remains as a highly active RTK in CLL B cells, 6, 7 can also cross-talk with the epidermal growth factor receptor and exists in a complex with the latter RTK in cetuximab (targets epidermal growth factor receptor)-resistant non-small cell lung cancer cells. 8 These information and our findings that CLL B cells co-express P-FGFR ( Figure 1h ) and P-Axl (Figure 1i ) prompted us to investigate whether Axl is also involved in a cross-talk with the FGFR signaling in CLL B cells. To address this, we first inhibited Axl phosphorylation in CLL B cells using a high-affinity Axl inhibitor TP-0903 9 and determined P-Axl/P-FGFR levels. Results demonstrate that TP-0903-mediated inhibition of P-Axl in CLL B cells (Figure 1l ) resulted in reduced levels of P-FGFR (Figure 1m ). On the other hand, treatment of CLL B cells with the FGFR-inhibitor TKI-258 10 could not alter Axl phosphorylation (Figure 1n , bottom panel), whereas the reduction of P-FGFR levels was evident (upper panel), suggesting that Axl is likely an upstream regulator of the FGFR signaling. Next, to rule out the possibility that TP-0903-mediated inhibition of P-FGFR was not an off-target effect, Axl in CLL B cells was targeted using an Axl-specific siRNA. Indeed, a partial depletion of Axl in CLL B cells resulted into reduction of P-FGFR levels ( Figure 1o, Supplementary Figure 4) . As primary CLL B cells are difficult to transfect, we chose a breast cancer cell line MDA-MB-231 reported to express both Axl and FGFR1/3 11, 12 as a model to further confirm Axl/FGFR functional relationship. As expected, siRNA-mediated depletion of Axl in MDA-MB-231 cells significantly reduced P-FGFR level (Figure 1p Letters to the Editor P-Axl (Supplementary Figure 5B) . However, the mechanism of Axl activation by BCR signal remains unknown.
Next, we wished to interrogate whether Axl forms a complex with FGFR3, which we have found predominantly expressed and heavily phosphorylated FGFR in CLL B cells (Figures 1a, d , j and k). Using IP/western blot techniques we detected that Axl and FGFR3 indeed form a complex in CLL B cells (Figures 2A and B) . To confirm the specificity, Axl was deplted in MDA-MB-231 cells using an Axl-specific siRNA to detect Axl/FGFR3 association. We did find co-precipitation of FGFR3 in the immune complex of Axl obtained from the control cells; however, the level of co-precipitated FGFR3 was reduced significantly in the immune complex upon depletion of Axl in MDA-MB-231 cells ( Figure 2C) ; whereas it appears that complex formation between Axl and FGFR3 may not depend on phosphorylation status of Axl (Supplementary Figure 6) . We also found that Axl and FGFR3 co-localize in CLL B cells ( Figure 2D ) where a punctate plasma membrane distribution of FGFR3 (red) and Axl (green) was observed. Further analysis of images using Image-pro premier software suggests that Axl and FGFR3 were highly co-localized in CLL B cells with an average overlap coefficient of 0.83 ( Figure 2E ).
Together, these findings suggest that Axl forms a complex with FGFR3, co-localize in the cells and regulates FGFR signaling pathway in human malignant cells.
Depending on cellular context, several pathways are activated by FGFRs including the p38 MAPK, Jun N-terminal kinase, AKT, phospholipase Cγ and Stat pathways. However, the Ras-MAPK and Stat are the major pathways mediating the oncogenic effects of FGFR3. 13 Given this, a TKI-258-mediated inhibition of the constitutively active FGFR signal induced significant levels of apoptosis in CLL B cells from previously untreated CLL patients (n = 12; Supplementary Table 1) in a time-and dose-dependent manner ( Figure 2F ). Relevant to this, analysis of the TKI-258 treated CLL B-cell lysates used in Figure 1n demonstrates that inhibition of P-FGFR in CLL B cells reduces phosphorylation of c-Src, Stat3 and Erk1/2, but not of AKT ( Figure 2G ), and expression of Mcl-1 but not XIAP or Bcl-2 ( Figure 2G ). In addition, a partial depletion of FGFR3 also reduces phosphorylation on Erk1/2, Stat3, c-Src and expression of Mcl-1 in CLL B cells ( Figure 2H ), thus ruled out any off-target effect of TKI-258. However, CLL bone marrow stromal cells showed a significant level of protection of the leukemic B cells from TKI-258-induced apoptosis ( Figure 2I) . Recently, the overexpression of FGFR3 has been reported in Waldenstrom macroglobulinemia and that Cell lysates from normal B-or CLL B cells were analyzed for the FGFR phosphorylation status at the catalytic tyrosine residues (Y653/654) by western blots using a phospho-specific antibody. Actin was used as loading control. Normal subjects (N1-N3) or CLL patients (P1-P9) are indicated by assigning arbitrary numbers. (i) Expression levels of phosphorylated Axl in CLL B cells. Axl was immunoprecipitated from equal amounts of the same CLL B-cell lysates used above (P1-P9) in h, followed by western blot analysis using a phospho-tyrosine specific antibody (4G10) to detect phosphorylation status on Axl. The blot was stripped and reprobed with anti-Axl antibody to detect total Axl in the immune complex. IgG HC was used as loading control. (j) FGFR3 remains phosphorylated at the catalytic site. FGFR3 was immunoprecipitated from equal amounts of purified normal B-or CLL B-cell lysates, followed by western blot analysis using a phospho-FGFR-specific antibody to detect Y653/654 phosphorylation on FGFR3. Normal rabbit IgG was included as an antibody control for the IP using CLL B-cell lysates (P4). The blot was stripped and reprobed with an antibody to FGFR3 to detect total FGFR3 in the immune complex. IgG HC was used as loading control. Cell lysates from normal subjects (N1, N2) or CLL patients (P1-P4) are indicated by assigning arbitrary numbers. (k) Detection of total tyrosine phosphorylation level on FGFR3 in CLL B cells. FGFR3 was immunoprecipitated from the lysates of normal B-and CLL B cells including those (N1, N2, P1-P4) used in the above experiment (j) and analyzed for total phosphorylation levels on FGFR3 in western blot using a P-Tyr (4G10) antibody. Normal rabbit IgG was included as an antibody control for the IP using CLL B-cell lysates (P6). The blot was stripped and reprobed for the detection of immunoprecipitated FGFR3. IgG HC was used as loading control. Cell lysates from normal subjects (N1, N2) or CLL patients (P1-P6) are indicated by assigning arbitrary numbers. (l) High-affinity Axl inhibitor TP-0903 reduces Axl phosphorylation. Total Axl was immunoprecipitated from lysates of CLL B cells treated with a sub-lethal dose (0.1 μM for 16 h) of a high-affinity Axl inhibitor TP-0903, followed by western blot analysis using a P-Tyr (4G10) antibody. The blot was stripped and reprobed to detect immunoprecipitated Axl. IgG HC was used as loading control. CLL patients (P1-P3) are indicated by arbitrary numbers. (m) Inhibition of P-Axl reduces FGFR phosphorylation. TP-0903 treated CLL B-cell lysates used above were further analyzed for the status of FGFR phosphorylation by western blot using a phosphospecific (Y653/654) FGFR antibody. Actin was used as loading control. (n) Inhibition of P-FGFR could not alter Axl phosphorylation. CLL B cells were treated with a sub-lethal dose of TKI-258 or left untreated and phosphorylation status of FGFRs was analyzed by western blots using a phospho-specific (Y653/654) FGFR antibody. Actin was used as loading control. Axl was also immunoprecipitated from the same CLL B-cell lysates and phosphorylation status of Axl was examined by western blot analysis using the 4G10 antibody. IgG HC was used as loading control. CLL patients (P1-P3) are indicated by arbitrary numbers. (o) Depletion of Axl reduces FGFR phosphorylation in CLL B cells. Purified primary CLL B cells from two representative CLL patients (P1, P2) were transfected with the control sc-siRNA (indicated by '-') or Axl-specific siRNA using the Lipofectamine 2000 lipid reagent, and cell lysates were analyzed for the status of Axl expression and P-FGFR (Y653/654) levels by western blots using specific antibodies. Actin was used as loading control. Fold changes of Axl and P-FGFR after siRNA transfection were determined by densitometric analysis and indicated. (p) Targeting Axl in MDA-MB-231 cells reduces FGFR phosphorylation level. In a similar experiment, MDA-MB-231 breast cancer cells were transfected with sc-siRNA (indicated by '-') or Axl-specific siRNA and cell lysates were analyzed for the status of Axl expression and P-FGFR (Y653/654) by western blots using specific antibodies. Actin was used as loading control. (q) Enforced activation of Axl increases FGFR phosphorylation. MDA-MB-231 cells were serum starved and treated with Gas6 (200 ng/ml) for 0, 5, 10 and 20 min. Cell lysates were then analyzed for the phosphorylation status of Axl at Y702 and FGFR at Y653/654 using specific antibodies. The blot showing P-Axl was stripped and reprobed to detect Axl expression. Actin was used as loading control.
inhibition of FGFR3 induces apoptosis in Waldenstrom macroglobulinemia cells and overcomes stromal protection.
14 Of interest, we also found that while in vitro combined treatment of CLL B cells with TKI-258 and ibrutinib produced synergistic effects in five of seven cases ( Figure 2J ), combination of TKI-258 with TP-0903 was mostly antagonistic ( Figure 2K ) in augmenting apoptosis levels. Collectively, these findings suggest that FGFR signaling is constitutive and may have an important role in regulating CLL B-cell survival.
In summary, we report that CLL B cells express high levels of FGFR3, which remains as a constitutively active RTK. Through a series of experiments, we, for the first time, report that Axl regulates FGFR signaling via complex formation with FGFR3. Cross-talk between RTKs is widespread; for example, ErbB3 robustly couples to the PI3-kinase pathway and it is used by epidermal growth factor receptor and ErbB2 as well as other RTKs to activate this pathway. 15 Most recently, Axl was found to activate epidermal growth factor receptor in cetuximab-resistant clones via complex formation, previously reported in triple-negative breast cancer cells. 8 We found that FGFR signaling is a downstream target of Axl and a novel addition to the growing list of RTKs in the Axl signaling network. Thus, targeting Axl signaling axis either alone or in combination with other signal inhibitors warrants further attention as a maneuver to more effectively induce apoptosis in CLL B cells, particularly in the relapsed/refractory setting. tissue bank were supported by the Predolin Foundation grant. We also wish to acknowledge Tolero Pharmaceuticals and Novartis for providing the inhibitors to Axl and FGFR, respectively, with relevant information and the excellent secretarial help of Ms Tammy Hughes.
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